Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE38.4700
- TODAY'S CHANGE (%)-1.3800 (-3.4630%)
- Bid / Lots15.4400/ 2
- Ask / Lots50.0000/ 1
- Open / Previous Close39.7100 / 39.8500
- Day Range
- 52 Week Range
- Volume299,227
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 1766 | 39.52 |
| 09:38 ET | 200 | 39.56 |
| 09:41 ET | 200 | 39.56 |
| 09:48 ET | 100 | 39.6 |
| 09:54 ET | 1000 | 39.56 |
| 09:56 ET | 1000 | 39.63 |
| 09:57 ET | 800 | 39.705 |
| 09:59 ET | 600 | 39.78 |
| 10:03 ET | 2100 | 39.775 |
| 10:06 ET | 2758 | 39.71 |
| 10:08 ET | 200 | 39.75 |
| 10:10 ET | 1000 | 39.67 |
| 10:14 ET | 1000 | 39.75 |
| 10:15 ET | 223 | 39.795 |
| 10:17 ET | 100 | 39.72 |
| 10:26 ET | 1200 | 39.73 |
| 10:28 ET | 1000 | 39.72 |
| 10:30 ET | 600 | 39.735 |
| 10:35 ET | 400 | 39.62 |
| 10:44 ET | 100 | 39.69 |
| 10:46 ET | 400 | 39.68 |
| 10:48 ET | 800 | 39.64 |
| 10:50 ET | 100 | 39.66 |
| 10:51 ET | 5572 | 39.545 |
| 10:53 ET | 7600 | 39.43 |
| 11:02 ET | 500 | 39.45 |
| 11:04 ET | 1066 | 39.51 |
| 11:06 ET | 100 | 39.465 |
| 11:09 ET | 1100 | 39.445 |
| 11:11 ET | 200 | 39.465 |
| 11:18 ET | 100 | 39.405 |
| 11:20 ET | 10418 | 39.395 |
| 11:26 ET | 100 | 39.51 |
| 11:29 ET | 8092 | 39.225 |
| 11:33 ET | 1115 | 39.2 |
| 11:38 ET | 600 | 38.9 |
| 11:44 ET | 200 | 38.87 |
| 11:45 ET | 209 | 38.86 |
| 11:54 ET | 100 | 38.71 |
| 11:58 ET | 100 | 38.59 |
| 12:07 ET | 400 | 38.77 |
| 12:21 ET | 438 | 38.8868 |
| 12:27 ET | 100 | 38.91 |
| 12:30 ET | 200 | 38.76 |
| 12:36 ET | 100 | 38.75 |
| 12:45 ET | 100 | 38.64 |
| 12:48 ET | 100 | 38.685 |
| 12:50 ET | 100 | 38.64 |
| 12:59 ET | 700 | 38.71 |
| 01:06 ET | 100 | 38.7275 |
| 01:10 ET | 200 | 38.835 |
| 01:17 ET | 300 | 38.77 |
| 01:21 ET | 200 | 38.74 |
| 01:24 ET | 600 | 38.75 |
| 01:28 ET | 200 | 38.73 |
| 01:32 ET | 300 | 38.81 |
| 01:35 ET | 100 | 38.94 |
| 01:37 ET | 850 | 38.83 |
| 01:39 ET | 200 | 38.71 |
| 01:44 ET | 310 | 38.76 |
| 01:46 ET | 100 | 38.78 |
| 01:48 ET | 495 | 38.825 |
| 01:55 ET | 200 | 38.81 |
| 01:57 ET | 1210 | 38.81 |
| 02:00 ET | 300 | 38.75 |
| 02:04 ET | 100 | 38.72 |
| 02:06 ET | 100 | 38.635 |
| 02:08 ET | 100 | 38.58 |
| 02:09 ET | 600 | 38.69 |
| 02:13 ET | 100 | 38.71 |
| 02:15 ET | 100 | 38.67 |
| 02:22 ET | 300 | 38.58 |
| 02:26 ET | 200 | 38.52 |
| 02:27 ET | 100 | 38.54 |
| 02:31 ET | 44380 | 38.72 |
| 02:38 ET | 300 | 38.86 |
| 02:44 ET | 100 | 38.87 |
| 02:49 ET | 500 | 38.78 |
| 02:58 ET | 100 | 38.79 |
| 03:00 ET | 400 | 38.855 |
| 03:02 ET | 2900 | 38.89 |
| 03:05 ET | 100 | 38.91 |
| 03:09 ET | 100 | 38.895 |
| 03:12 ET | 400 | 38.935 |
| 03:14 ET | 400 | 38.895 |
| 03:16 ET | 600 | 38.905 |
| 03:18 ET | 1841 | 38.9775 |
| 03:21 ET | 810 | 38.89 |
| 03:23 ET | 700 | 38.895 |
| 03:25 ET | 700 | 38.905 |
| 03:27 ET | 500 | 38.95 |
| 03:30 ET | 200 | 38.96 |
| 03:32 ET | 300 | 38.9 |
| 03:34 ET | 305 | 38.925 |
| 03:36 ET | 200 | 38.89 |
| 03:38 ET | 100 | 38.91 |
| 03:39 ET | 600 | 38.905 |
| 03:41 ET | 1700 | 38.915 |
| 03:43 ET | 9192 | 38.72 |
| 03:45 ET | 1300 | 38.8 |
| 03:48 ET | 600 | 38.855 |
| 03:50 ET | 1100 | 38.831 |
| 03:52 ET | 1544 | 38.75 |
| 03:54 ET | 781 | 38.68 |
| 03:56 ET | 6360 | 38.66 |
| 03:57 ET | 11644 | 38.5 |
| 03:59 ET | 31321 | 38.47 |
Sep 3, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 9:58AM ET on Tuesday Sep 03, 2024 by Dow Jones
9:58AM ET on Tuesday Sep 03, 2024 by Dow Jones
Aug 12, 2024
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer, from 8:30AM ET on Monday Aug 12, 2024 by Dow Jones
8:30AM ET on Monday Aug 12, 2024 by Dow JonesPress Release: Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer, from 8:30AM ET on Monday Aug 12, 2024 by Dow Jones
8:30AM ET on Monday Aug 12, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 5:51AM ET on Monday Aug 12, 2024 by Dow Jones
5:51AM ET on Monday Aug 12, 2024 by Dow Jones
Aug 9, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $65.00/Share by Cantor Fitzgerald, from 11:24AM ET on Friday Aug 09, 2024 by Dow Jones
11:24AM ET on Friday Aug 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -14.1x | --- |
MoonLake Immunotherapeutics | 2.9B | -50.9x | --- |
Celldex Therapeutics Inc | 2.9B | -16.0x | --- |
SpringWorks Therapeutics Inc | 2.9B | -8.7x | --- |
Iovance Biotherapeutics Inc | 3.0B | -5.9x | --- |
Apogee Therapeutics Inc | 2.8B | -21.0x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
- Chief Medical Officer
- Christopher Kenney
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.74 |
Book Value | $12.31 |
P/E Ratio | -14.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
